Marvel Biosciences Corp. (MRVL.V)
| Previous Close | 0.1250 |
| Open | 0.1250 |
| Bid | 0.1250 x N/A |
| Ask | 0.1300 x N/A |
| Day's Range | 0.1100 - 0.1250 |
| 52 Week Range | 0.0100 - 0.1900 |
| Volume | |
| Avg. Volume | 47,256 |
| Market Cap | 5.598M |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings Date | May 10, 2024 - May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileMarvel Biosciences Announces Stock Option Grants
Calgary, Alberta--(Newsfile Corp. - July 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announce that, effective July 23, 2024, its board of directors approved the grant of incentive stock options (the "Options") to certain directors and officers to acquire an aggregate of 1,475,000 common shares in the capital of the Company at an exercise price of $0.125, being the closing price ...
NewsfileMarvel Announces an Extension to Its Collaboration with The iBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome
Calgary, Alberta--(Newsfile Corp. - July 24, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today is pleased to announce the extension of its collaboration with Drs. Julie Le Merrer and Jerome Becker, lead investigators at the iBraiN Institute in Tours France. Building upon the promising results using MB204 in an autism model earlier this year, we now aim to test ...
NewsfileMarvel Biosciences Closes Private Placement
Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to report that, further to its press releases of May 16, 2024 and June 21, 2024, it has closed its non-brokered private placement unit offering (the "Offering"). The offering resulted in the issuance of 5,000,000 units at $0.10 per unit (the "Units") for gross proceeds ...
